SLC6A3 and Parkinson disease: However, Galoppin et al. [3] reported that striatal [11C] (+) dihydrotetrabenazine results in NIP extend previous DAT imaging studies using SPECT [4] and that striatal binding in NIP is divided into spared and low vesicular monoamine transporter type 2 (VMAT2), where PD-like bindings would be clinically indistinguishable from PD.